Abiraterone Acetate
Abiraterone Acetate structure
|
Common Name | Abiraterone Acetate | ||
|---|---|---|---|---|
| CAS Number | 154229-18-2 | Molecular Weight | 391.546 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 506.7±50.0 °C at 760 mmHg | |
| Molecular Formula | C26H33NO2 | Melting Point | 127-130°C | |
| MSDS | Chinese USA | Flash Point | 260.2±30.1 °C | |
| Symbol |
GHS08 |
Signal Word | Danger | |
|
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
J. Clin. Oncol. 28(9) , 1481-8, (2010) Abiraterone acetate is a prodrug of abiraterone, a selective inhibitor of CYP17, the enzyme catalyst for two essential steps in androgen biosynthesis. In castration-resistant prostate cancers (CRPCs), extragonadal androgen sources may sustain tumor growth des... |
|
|
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
J. Clin. Oncol. 28(9) , 1489-95, (2010) The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC).In this multicenter, two-sta... |
|
|
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
J. Clin. Oncol. 28(9) , 1496-501, (2010) Persistence of ligand-mediated androgen receptor signaling has been documented in castration-resistant prostate cancers (CRPCs). Abiraterone acetate (AA) is a potent and selective inhibitor of CYP17, which is required for androgen biosynthesis in the testes, ... |
|
|
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
J. Clin. Oncol. 27(23) , 3742-8, (2009) It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent. Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in androgen and estrogen biosynthesis.This was a ph... |
|
|
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
J. Urol. 194(6) , 1537-47, (2015) The availability of newly approved treatment options for metastatic castration resistant prostate cancer is not matched with conclusive data on optimal sequencing strategies and resistance patterns. A comprehensive review of efficacy and safety data for new a... |
|
|
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
Cancer Res. 69(12) , 4937-40, (2009) Abiraterone acetate is a potent, selective, and orally bioavailable small molecule inhibitor of CYP17, an enzyme that catalyzes two key serial reactions (17 alpha hydroxylase and 17,20 lyase) in androgen and estrogen biosynthesis. Clinical trials have confirm... |
|
|
Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways.
Int. J. Oncol. 48(2) , 793-800, (2016) Abiraterone provides significant survival advantages in prostate cancer (PC), however, the current understanding of the molecular mechanisms of abiraterone is still limited. Therefore, the abiraterone impact on androgen receptor (AR)-positive LNCaP and AR-neg... |